Electroclinical Features of Sudden Unexpected Death in Epilepsy (SUDEP) : a Multi-center Observational Study
Launched by LIU YONGHONG · Jun 14, 2022
Trial Information
Current as of November 14, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study is an observational project that looks at people with epilepsy who have had Sudden Unexpected Death in Epilepsy (SUDEP) or a near-SUDEP event. The goal is to understand what happens before and during these events and to explore brain activity patterns captured on video EEG (brain waves recorded with video). Researchers hope to identify markers that could help prevent SUDEP in the future. It’s a multicenter study in China, led by Xijing Hospital in Xi’an, and plans to enroll about 30 participants who have already experienced SUDEP or near-SUDEP.
Who can take part? The study includes all sexes and ages (children, adults, and older adults) and will enroll people with epilepsy who have SUDEP or near-SUDEP, with consent from a relative or caregiver. To participate, doctors must confirm the SUDEP/near-SUDEP diagnosis and obtain written permission from a family member or caregiver. Participants will undergo a 24-hour video-EEG monitoring test using standard equipment to collect data, along with routine tests like eyes-open/closed checks, intermittent photic stimulation, and hyperventilation. The study is observational (not testing a drug or device) and aims to track SUDEP events and related EEG findings from 2022 to 2024.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with epilepsy who meet SUDEP or near-SUDEP diagnosis,
- • Giving written informed consent to participate in the study from relatives or caregivers.
- Exclusion Criteria:
- • Refusing to recruitment from relatives or caregivers.
About Liu Yonghong
Liu Yonghong is a dedicated clinical trial sponsor committed to advancing healthcare through innovative research and development. With a focus on enhancing therapeutic options and improving patient outcomes, Liu Yonghong collaborates with leading institutions and experts to conduct rigorous clinical trials across various therapeutic areas. The sponsor emphasizes adherence to ethical standards and regulatory compliance, ensuring the safety and well-being of participants while generating valuable data to inform future medical practices. Through a commitment to scientific excellence and collaboration, Liu Yonghong aims to contribute significantly to the enhancement of global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Xi'an, Shaanxi, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials